Goldman Sachs Believes A Won’t Stop Here

Goldman Sachs analyst Isaac Ro maintained a Buy rating on Agilent (NYSE: A) today and set a price target of $50. The company’s shares closed yesterday at $48.43, close to its 52-week high of $48.63.

According to, Ro is a 2-star analyst with an average return of -0.2% and a 58.7% success rate. Ro covers the Healthcare sector, focusing on stocks such as Quest Diagnostics Inc., Foundation Medicine, and Laboratory Corp.

Currently, the analyst consensus on Agilent is Strong Buy and the average price target is $52.33, representing an 8.1% upside.

In a report released today, Evercore ISI also maintained a Buy rating on the stock with a $53 price target.

The company has a one year high of $48.63 and a one year low of $33.12. Currently, Agilent has an average volume of 2.07M.

Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock. Most recently, in May 2016, James Cullen, a a Director at A sold 16,697 shares for a total of $764,389.

Agilent Technologies, Inc. provides core bio-analytical and electronic measurement solutions to the life sciences, chemical analysis, communications and electronics, diagnostics and genomics industries. It operates through the following segments: Life Sciences, Chemical Analysis, Diagnostics & Genomics and Electronic Measurement. The Life Sciences segment provides application-focused solutions that include instruments, software, consumables and services that enable customers to identify, quantify and analyze the physical and biological properties of substances and products. The Chemical Analysis segment manufactures gas chromatography mass spectrometry systems, inductively coupled plasma mass spectrometry instruments, atomic absorption instruments, inductively coupled plasma optical emission spectrometry instruments, molecular spectroscopy instruments, vacuum pumps and measurement technologies supports and services. The Diagnostics & Genomics segment provides solutions that include reagents, instruments, software and consumables that enable customers in the clinical and life sciences research areas to interrogate samples at the molecular level. The Electronic Measurement segment provides electronic measurement instruments and systems, software design tools and related services that are used in the design, development, manufacture, installation, deployment and operation of electronics equipment and microscopy products. The company was founded in 1999 and is headquartered in Santa Clara, CA.